CTLA4 and metastatic melanoma: Recent studies have revealed that around 40% of patients with metastatic melanoma who underwent PD-1 inhibitor monotherapy experienced positive outcomes, while over 60% of those who underwent standard therapy combined with dual blockade of CTLA-4 and PD-1 showed favorable results [94].